- Home
- PAYS vs SPRO Comparison
PAYS vs SPRO Comparison
Compare PAYS & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAYS
- SPRO
- Stock Information
- Founded
- PAYS 2001
- SPRO 2013
- Country
- PAYS United States
- SPRO United States
- Employees
- PAYS N/A
- SPRO N/A
- Industry
- PAYS Business Services
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- PAYS Consumer Discretionary
- SPRO Health Care
- Exchange
- PAYS Nasdaq
- SPRO Nasdaq
- Market Cap
- PAYS 125.2M
- SPRO 104.1M
- IPO Year
- PAYS 1998
- SPRO 2017
- Fundamental
- Price
- PAYS $5.27
- SPRO $2.05
- Analyst Decision
- PAYS Strong Buy
- SPRO Buy
- Analyst Count
- PAYS 4
- SPRO 4
- Target Price
- PAYS $7.31
- SPRO $5.00
- AVG Volume (30 Days)
- PAYS 827.1K
- SPRO 724.5K
- Earning Date
- PAYS 08-05-2025
- SPRO 08-12-2025
- Dividend Yield
- PAYS N/A
- SPRO N/A
- EPS Growth
- PAYS N/A
- SPRO N/A
- EPS
- PAYS 0.12
- SPRO N/A
- Revenue
- PAYS $68,539,381.00
- SPRO $48,576,000.00
- Revenue This Year
- PAYS $35.12
- SPRO N/A
- Revenue Next Year
- PAYS $20.99
- SPRO N/A
- P/E Ratio
- PAYS $43.93
- SPRO N/A
- Revenue Growth
- PAYS 27.84
- SPRO N/A
- 52 Week Low
- PAYS $1.80
- SPRO $0.51
- 52 Week High
- PAYS $8.88
- SPRO $3.22
- Technical
- Relative Strength Index (RSI)
- PAYS 37.06
- SPRO 47.83
- Support Level
- PAYS $5.27
- SPRO $1.83
- Resistance Level
- PAYS $5.58
- SPRO $1.94
- Average True Range (ATR)
- PAYS 0.22
- SPRO 0.10
- MACD
- PAYS 0.01
- SPRO 0.02
- Stochastic Oscillator
- PAYS 41.25
- SPRO 43.10
About PAYS Paysign Inc.
PaySign Inc is a provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing designed for businesses, consumers, and government institutions. The Company creates customized payment solutions for clients across industries, including pharmaceutical, healthcare, hospitality, and retail. The company's revenues include fees generated from cardholder fees, interchange, card program management fees, transaction claims processing fees, and settlement income.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.